8-K: KALA BIO Reports Q4 and Full Year 2023 Results, Advances KPI-012 Clinical Trial

KALA BIO announced its fourth quarter and full year 2023 financial results, highlighting progress in its KPI-012 clinical trial and providing a corporate update.

Summary

• KALA BIO reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company is focused on advancing its Phase 2b CHASE trial of KPI-012 for persistent corneal epithelial defect (PCED), with topline data expected by year-end 2024.
• KALA is also exploring opportunities to expand KPI-012 into additional corneal indications.
• As of December 31, 2023, KALA had $50.9 million in cash and cash equivalents.
• The company expects its cash resources, along with proceeds from a March 2024 private placement and anticipated funding from a CIRM award, to fund operations into the third quarter of 2025.
• For the fourth quarter of 2023, KALA reported a net loss of $8.6 million, or $3.18 per share, compared to a net loss of $12.8 million, or $7.97 per share, for the same period in 2022.
• For the full year 2023, KALA reported a net loss of $42.2 million, or $17.35 per share, compared to a net loss of $44.8 million, or $29.48 per share, for the same period in 2022.
• The company did not recognize product revenues in 2023 due to the sale of its commercial portfolio in 2022.
• Research and development expenses increased to $18.6 million for the full year 2023, compared to $17.7 million in 2022, primarily due to increased KPI-012 development costs.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials and the extended cash runway, but there are still risks associated with clinical trial outcomes and the need for additional funding.

Positives

• KALA BIO is making progress in its clinical trial for KPI-012, with topline data expected by the end of 2024.
• The company has secured funding that is expected to last into the third quarter of 2025.
• The net loss for the full year 2023 improved compared to 2022.
• KALA is exploring additional applications for its MSC-S platform technology, including other corneal and retinal diseases.
• The company has received Orphan Drug and Fast Track designations from the FDA for KPI-012 for PCED.

Negatives

• KALA BIO did not recognize any product revenue in 2023 due to the sale of its commercial portfolio in 2022.
• The company reported a net loss of $42.2 million for the full year 2023.
• Research and development expenses increased in 2023, primarily due to KPI-012 development costs.
• The company is reliant on additional funding from a CIRM award to extend its cash runway.

Risks

• The success of the KPI-012 clinical trial is not guaranteed, and topline data may not be positive.
• The company's ability to secure additional funding from the CIRM award is subject to meeting certain milestones.
• KALA BIO is dependent on its cash resources and may need to raise additional capital in the future.
• There are risks associated with regulatory review of clinical trials and applications for marketing approvals.
• The company's ability to retain and hire key personnel is crucial for its success.

Future Outlook

KALA anticipates that its cash resources, together with proceeds from the March 2024 private placement and anticipated funding under the CIRM award, will enable it to fund operations into the third quarter of 2025. The company is targeting topline data from the CHASE Phase 2b clinical trial by year-end 2024 and is exploring additional indications for KPI-012.

Management Comments

• Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, stated that the company focused on clinical execution in 2023, advancing the Phase 2b CHASE trial of KPI-012 for PCED.
• Mr. Iwicki also mentioned that the company believes KPI-012 may address a significant unmet need, potentially offering a differentiated product profile for PCED.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing therapies for rare and severe eye diseases. KALA BIO's focus on its MSC-S platform and KPI-012 for PCED aligns with the growing interest in regenerative medicine and novel treatments for ocular conditions. The company's progress in clinical trials and its financial position are key factors for investors in this sector.

Comparison to Industry Standards

• KALA BIO's focus on rare ocular diseases is similar to companies like REGENXBIO and Adverum Biotechnologies, which are also developing gene therapies for retinal diseases.
• The development of KPI-012 for PCED is unique, as there are currently no FDA-approved prescription products with a broad indication for all underlying etiologies of PCED, setting KALA apart from competitors in this specific area.
• The company's cash runway into Q3 2025 is comparable to other clinical-stage biopharma companies, but the reliance on a CIRM award adds a layer of uncertainty.
• KALA's R&D spending of $18.6 million for the full year 2023 is within the range of other companies at a similar stage of development, but the increase from 2022 reflects the focus on KPI-012.
• The net loss of $42.2 million for the full year 2023 is typical for a clinical-stage company without commercial products, but the improvement from 2022 is a positive sign.

Stakeholder Impact

• Shareholders are impacted by the financial results and the progress of the clinical trials.
• Employees are impacted by the company's financial stability and the progress of its research and development programs.
• Patients with PCED and other ocular diseases are impacted by the potential development of new therapies.
• Creditors are impacted by the company's financial position and its ability to meet its obligations.

Next Steps

• KALA BIO will continue to enroll patients in the CHASE Phase 2b clinical trial.
• The company is targeting to announce topline data from the CHASE trial by year-end 2024.
• KALA will continue to evaluate the potential of KPI-012 for additional rare, front-of-the-eye diseases.
• The company will continue preclinical studies to evaluate the utility of its MSC-S platform for retinal degenerative diseases.

Key Dates

Keywords

KALA BIO, KPI-012, PCED, MSC-S, Clinical Trial, Ocular Diseases, Biopharmaceutical, Financial Results, Private Placement, CIRM Award